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ABSTRACT
Hypoxic preconditioning reprogrammes the brain’s response
to subsequent H/I (hypoxia–ischaemia) injury by enhancing
neuroprotective mechanisms. Given that astrocytes normally
support neuronal survival and function, the purpose of the
present study was to test the hypothesis that a hypoxic
preconditioning stimulus would activate an adaptive astro-
cytic response. We analysed several functional parameters 24
h after exposing rat pups to 3 h of systemic hypoxia (8% O2).
Hypoxia increased neocortical astrocyte maturation as
evidenced by the loss of GFAP (glial fibrillary acidic protein)-
positive cells with radial morphologies and the acquisition of
multipolar GFAP-positive cells. Interestingly, many of these
astrocytes had nuclear S100B. Accompanying their differ-
entiation, there was increased expression of GFAP, GS
(glutamine synthetase), EAAT-1 (excitatory amino acid
transporter-1; also known as GLAST), MCT-1 (monocarbox-
ylate transporter-1) and ceruloplasmin. A subsequent H/I
insult did not result in any further astrocyte activation. Some
responses were cell autonomous, as levels of GS and MCT-1
increased subsequent to hypoxia in cultured forebrain
astrocytes. In contrast, the expression of GFAP, GLAST and
ceruloplasmin remained unaltered. Additional experiments
utilized astrocytes exposed to exogenous dbcAMP (dibutyryl-
cAMP), which mimicked several aspects of the preconditioning
response, to determine whether activated astrocytes could
protect neurons from subsequent excitotoxic injury. dbcAMP
treatment increased GS and glutamate transporter expression
and function, and as hypothesized, protected neurons from
glutamate excitotoxicity. Taken altogether, these results
indicate that a preconditioning stimulus causes the pre-
cocious differentiation of astrocytes and increases the
acquisition of multiple astrocytic functions that will contrib-
ute to the neuroprotection conferred by a sublethal
preconditioning stress.
Key words: cell death, glutamate, glutamine synthetase,
excitotoxicity, stroke, transporter.
INTRODUCTION
Preconditioning refers to a paradigm whereby exposing cells
or an organ or organism to a sublethal insult provides
protection against a subsequent insult that would normally
produce injury. Although both acute and long-term pre-
conditioning have been demonstrated, several studies have
confirmed that the protective effect of an episode of hyp-
oxic preconditioning occurs when the interval between the
preconditioning event and the subsequent lethal event is
,24 h. Hypoxic preconditioning in the neonatal rat (8% O2,
for 3 h) was originally shown to provide tolerance to H/I
(hypoxia–ischaemia) brain injury in the neonatal rat brain:
this phenomenon has subsequently been demonstrated for
the adult brain (Gidday et al., 1994; Vannucci et al., 1998;
Bergeron et al., 2000; Jones and Bergeron, 2001). Since
preconditioning provides dramatic neuroprotection there is
much interest in understanding the molecular mechanisms
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underlying the cell retention that is achieved in order that it
might be mimicked using pharmacological agents. Several
studies have shown that hypoxic exposure alters gene
expression and that it activates several intracellular signalling
pathways, some of which may contribute to the adaptive
responses observed after hypoxia (Semenza, 2000; Bernaudin
et al., 2002; Ran et al., 2005).
Many studies seeking to identify mechanisms of hypoxic
preconditioning-induced adaptive responses have focused on
the neuronal response to this insult. For instance, investiga-
tors have shown increased levels of anti-apoptotic Bcl-2,
increased levels of HIF-1 (hypoxia-inducible factor-1)-
regulated genes, and an increased capacity of neurons to
sequester calcium (Gidday, 2006). However, astrocytes serve
many essential physiological functions in the CNS (central
nervous system) on which neurons depend for their survival
and peak functional performance. These include inducing the
formation and maintenance of the blood–brain barrier,
clearing extracellular potassium that accumulates with
neuronal activity and collecting and metabolizing excitatory
amino acids (Sofroniew and Vinters, 2010). Astrocytes also
store energy in the form of glycogen that can be metabolized
to pyruvate for their own survival or to lactate for export to
neurons for additional fuel during energy crises, such as
during H/I (Swanson and Choi, 1993). Astrocytes also produce
enzymes to detoxify metals and xenobiotics (Sofroniew
and Vinters, 2010). Additionally astrocytes, and especially
perivascular astrocytes, express ceruloplasmin, which is a
multifunctional protein that serves as an amine oxidase, an
antioxidant and a ferroxidase. Ceruloplasmin expression
increases when astrocytes become activated (Kuhlow et al.,
2003). A subset of these astroglial functions are induced in
adult astrocytes in response to hypoxic or chemical
preconditioning (Romera et al., 2004, 2007; Kawahara et al.,
2005; Hoshi et al., 2006, 2010; Yamada et al., 2006; Zhang
et al., 2007; Weller et al., 2008; Yu et al., 2008). Therefore we
were interested in establishing whether immature astrocytes
would respond to a preconditioning event by enhancing their
expression of the proteins that support these essential
support functions, which, in turn, would enable them to
better support neurons to survive a subsequent lethal
excitotoxic challenge.
To test this hypothesis, we studied the status of multiple
indicators of the astrocytic physiological state, including
GFAP (glial fibrillary acidic protein), the neurotrophic,
calcium-binding protein, S100b, GS (glutamine synthetase),
EAAT-1 (excitatory amino acid transporter-1; also known as
GLAST), MCT-1 (monocarboxylate transporter-1) and CP
(ceruloplasmin) levels 24 h after a 3 h hypoxic exposure (a
time corresponding to the beginning of a subsequent H/I
insult in previous preconditioning experiments). We were
particularly interested in evaluating GS and GLAST as indices
of glial glutamate handling capacity, as levels of glutamate
have been shown to increase to as high as 500 mM after H/I in
the newborn and neurons are extremely vulnerable to
excitotoxic death in the immature brain (Hagberg et al.,
1993). To determine whether these changes were direct re-
sponses of astrocytes to hypoxia, we evaluated the effects of
hypoxia on enriched cultures of forebrain astrocytes. Finally,
astrocytes exposed to exogenous dbcAMP (dibutyryl-cAMP) –
which mimics some but not all of the preconditioning
responses – were utilized to determine whether alterations in
glutamate handling would influence neuronal survival.
Altogether, our results indicate that a preconditioning
stimulus elevates multiple astrocytic functions that endow
them with an enhanced capacity to protect neurons from a
subsequent challenge.
MATERIALS AND METHODS
Materials
Unless otherwise stated, all chemicals and laboratory reagents
were purchased from either Fisher Scientific (Pittsburgh, PA,
U.S.A.) or Sigma (St. Louis, MO, U.S.A.). Eagle’s minimum
essential media and DMEM/F12 [DMEM (Dulbecco’s modified
Eagle’s medium) with nutrient F12 mixture in the ratio 1:1]
were purchased from Mediatech/Life Technologies (Fisher
Scientific). Fetal bovine serum was purchased from Tissue
Culture Biologicals (Tulare, CA, U.S.A.). Calf serum was
purchased from Hyclone (Logan, UT, U.S.A.). Neurobasal and
B27 supplements were purchased from Invitrogen (Carlsbad,
CA, U.S.A.). Cytosine b-D-arabinofuranoside and dbcAMP
were purchased from Sigma. Rabbit polyclonal antibodies
against cow GFAP (catalogue no. Z0334) were purchased
from Dako (Carpinteria, CA, U.S.A.). Mouse anti-S100b was
purchased from Sigma (catalogue no. SAB1402349). Mouse
monoclonal antibody against GS (catalogue no. MAB302) was
purchased from Millipore (Temecula, CA, U.S.A.). Rabbit
polyclonal anti-GS antibodies were purchased from Sigma
(catalogue no. G2781), mouse monoclonal anti-EAAT-2
antibodies were purchased from BD Biosciences (catalogue
no. 611654; San Jose, CA, U.S.A.) and mouse monoclonal anti-
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) were
purchased from Millipore (catalogue no. MAB374). Mouse
anti-CP was purchased from BD (catalogue no. 611488).
Secondary antibodies for immunofluorescence were donkey
anti-rabbit Dylight 488 or donkey anti-mouse IgG Dylight
549 from Jackson Immunoresearch (West Grove, PA, U.S.A.).
TRIzolH was purchased from Molecular Research (Bethesda,
MD, U.S.A.), and reverse transcriptase reaction reagents,
buffers and enzymes were purchased from Sigma or Qiagen
(Valencia, CA, U.S.A.). D-[3H]aspartate and [35S]UTP were
purchased from New England Nuclear (Boston, MA, U.S.A.).
Hypoxic preconditioning
Wistar rat pups at P6 (postnatal day 6, where P1 is the day of
birth) underwent hypoxic preconditioning as described
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previously (Gidday et al., 1994; Vannucci et al., 1998). Control
animals were maintained at 37 C˚ for 3 h under atmospheric
conditions. To determine the effect of a subsequent H/I
episode, P7 rat pups underwent permanent unilateral (right)
carotid artery ligation, followed 2 h thereafter by 60 min of
systemic hypoxia as described previously (Vannucci and
Vannucci, 2005). The interval from the onset of hypoxic
preconditioning to the onset of cerebral H/I was 24 h and the
animals were allowed to survive for an additional 24 h. All
experiments on animals were carried out in accordance with
institutional guidelines and subsequent to IACUC committee
approvals, and the present authors further attest that all
efforts were made to minimize the number of animals used
and their suffering.
In situ hybridization
Animals were anaesthetized with a mixture of ketamine (75
mg/kg) and xylazine (5 mg/kg) prior to intracardiac perfusion
with 4% (w/v) paraformaldehyde. Brains were postfixed with
4% paraformaldehyde overnight and then cryoprotected for at
least 24 h in 30% sucrose in 0.1 M phosphate buffer (pH 7.4).
The brain samples were frozen in embedding medium (O.C.T.;
Sakura Finetek, Torrance, CA, U.S.A.) on a solid CO2/ethanol
slush. Brains were sectioned at 12 mm and thaw mounted on to
SuperfrostPlusTM slides and then placed at 280 C˚. In situ
hybridization using a 35S-labelled riboprobe for GFAP was
performed as previously described (Vannucci et al., 1998).
Immunofluorescence
Vibratome sections (50 mm) were cut on a Ted Pella 1000
series vibratome, incubated in 0.2% Triton X-100 in TBS (Tris-
buffered saline; pH 7.4) for 30 min and then blocked for 1 h
with 10% (v/v) donkey serum, 10% (w/v) BSA and 0.05% Triton
X-100 in TBS. Sections were incubated in mouse anti-S100b
(Sigma) and rabbit anti-GFAP (Dako; diluted 1:500) and
incubated for 24 h at 4 C˚, followed by extensive rinses in
TBS containing 1.5% NaCl and 0.05% Triton X-100. Secondary
antibodies were incubated for 24 h at 4 C˚ (diluted 1:400). The
secondary antibodies were carefully examined to ensure that
there was no cross-talk between fluorescent dyes or cross-
reactivity between secondary antibodies. No signal above
background was obtained when the primary antibodies were
replaced with pre-immune sera. The sections were then
washed, counterstained with DAPI (49,69-diamidino-2-pheny-
lindole; 1 mg/ml; Sigma) for 5–10 min and coverslipped with
Fluorogel (Electron Microscopy Sciences, Hatfield, PA, U.S.A.).
Then 5 mm z-stacks were captured using a Zeiss LSM-510
microscope. Z-series projections were generated, rotated by
10˚and assembled in a montage using Adobe Photoshop CS-2.
Astrocyte cultures
Primary astrocyte cultures were prepared from 1–2-day-old
rat pups using standard methods (Levison and McCarthy,
1991). For the experiments described in Figure 3, enriched
astrocyte cultures were prepared using the shaking method
and then transferred to a chemically defined medium for 5
days to enhance their maturation (S.W. Levison, unpublished
data). On day 6, the astrocytes were subjected to hypoxia
(8% O2) for 3 h, in a Forma O2/CO2 incubator (Forma
Scientific, Marietta, OH, U.S.A.) and then maintained under
atmospheric conditions (21% O2/5% CO2) for 24 h. For the
experiments described in Figures 4–6, astrocyte cultures were
prepared as described by Hamby et al. (2006), save for the use
of EGF (epidermal growth factor) and antibiotics. Once the
astrocytes reached confluence, cultures were treated once
with 8 mM cytosine b-D-arabinofuranoside for 4–8 days to
substantially reduce microglial contamination. Thereafter,
cultures were maintained in growth medium (Hamby et al.,
2006).
For activated astrocyte studies, monolayers of primary rat
astrocytes were maintained for 7–8 days in growth medium
alone or in growth medium containing 250 mM dbcAMP, both
of which were replenished every 2–3 days prior to
experimentation.
Neuronal cultures
Neuronal cultures were prepared by enzymatically and
mechanically dissociating cortices of E15 (embryonic day
15) mouse cerebrum and plating the resulting cells at 6 hemi-
spheres per plate in neurobasal medium supplemented with
B27 and 50 i.u. (international units)/ml penicillin/50 mg/ml
streptomycin. Glutamine (1.5 mM) was added just prior to
use. At 2 days after plating, cultures were treated once with 1
mM b-D-arabinofuranoside for an additional 2 days. The
medium was partially replenished (1/2 volume exchange)
twice per week and on the day of experimentation [DIV (days
in vitro) 8]. All cultures were kept at 37 C˚ in a humidified 6%
CO2-containing atmosphere.
Immunoblotting
Western blots from tissue homogenates
First, 10–15 mg of protein was separated on 7% Tris/acetate
polyacrylamide gels electrophoresed at 150 V for 80 min and
transferred at 300 mA for 80 min to nitrocellulose
membranes. The membranes were stained with 0.1%
Ponceau S in 5% acetic acid to confirm proper transfer of
proteins. Then, membranes were blocked for 1 h in 10% non-
fat dried skimmed milk diluted in PBS-T (0.05% Tween 20 in
PBS). Membranes were incubated overnight at 4 C˚ in primary
antibody diluted in 1% BSA/PBS-T. After incubation with the
primary antibody, the blots were extensively washed with
PBS-T for 30 min and then incubated for 1.5 h at room
temperature (20 C˚) with secondary antibody conjugated with
horseradish peroxidase diluted in 1% BSA/PBS-T. The
membranes were then washed extensively in PBS-T for 30
min prior to visualization using RenaissanceTM chemilumin-
escence (NEL104; NEN Life Science, Boston, MA, U.S.A.).
Preconditioning activates astrocytes
E 2011 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
161
Blots were probed with rabbit anti-EAAT-1 (1:1000; Alpha
Diagnostic, San Antonio, TX, U.S.A.), mouse anti-GS (1:2000;
Millipore) or rabbit anti-GFAP (1:5000; Dako), rabbit anti-
ceruloplasmin (1:10000; Dako) or rabbit anti-MCT-1 [1:8000;
a gift from Dr Ian Simpson (Department of Neural and
Behavioral Sciences, Penn State College of Medicine, Hershey,
PA, U.S.A.) (Vannucci and Simpson, 2003)]. The blots were
visualized using the RenaissanceTM chemiluminescence
reagent from NEN. Images were obtained and quantified
using a UVP imaging system with LabWorks software (UVP,
Upland, CA, U.S.A.).
Western blots from astrocyte cultures
Cultures grown in 15 mm multi-well dishes (Falcon Primaria,
Becton Dickinson, Lincoln Park, NJ, U.S.A.) were washed with
0.4 ml of ice-cold PBS. Then, 50–100 ml of lysis buffer
containing 1% Nonidet P40, 5 mM EDTA, 5 mM iodoaceta-
mide and 16CompleteTM protease inhibitor cocktail (Roche
Diagnostics, Mannheim, Germany) in TBS was added to each
well. Plates were placed on ice for 30 min while rocking and
cells were harvested by gentle scraping. Cellular debris was
pelleted (10000 g, 10 min and 4 C˚) and cell lysates were
stored at 220 C˚. Protein concentration was determined using
the BCA assay (Pierce, Rockford, IL, U.S.A.). First, 5–15 mg of
protein was separated by SDS/10% PAGE under reducing
conditions and electrophoretically transferred to nitrocellu-
lose. Membranes were washed twice with water (20 ml, 5
min) and proteins of interest were detected using the primary
antibodies at 1 mg/ml visualized using species-specific
WesternBreeze Immunodetection kits (Invitrogen) as per the
manufacturer’s instructions. Results were recorded on an
X-ray film (Fujifilm, Tokyo, Japan). Digitized images were
analysed by computer-assisted densitometry (Gel-Pro analy-
zer; Media Cybernetics) and protein levels were normalized to
their respective GAPDH levels.
Measurement of excitatory amino acid transport
D-[3H]aspartate was used as the substrate for glutamate
transporters as described and characterized previously
(Vidwans and Hewett, 2004). Cells were washed twice with
HBSS (Hepes-buffered salt solution; 120 mM NaCl, 5.4 mM
KCl, 0.8 mM MgCl2, 1.8 mM CaCl2, 20 mM Hepes, 15 mM glu-
cose and 0.01 mM glycine) and rocked for 10 min at room
temperature. The buffer was then fully exchanged with HBSS
containing D-[3H]aspartate (final concentration: 0.1 mCi/ml)
and 50 mM of unlabelled aspartate as a carrier. Uptake was
terminated after 3 min by washing three times with ice-cold
choline stop buffer containing 116 mM choline chloride, 0.8
mM MgSO4, 1 mM KH2PO4, 10 mM Hepes, 5 mM KOH, 10 mM
glucose, 0.9 mM CaCl2 and 5 mM of non-radioactive D-
aspartate (4 C˚). This time point was within the linear range of
uptake for both dbcAMP-treated and -untreated cultures
(results not shown). Culture wells were subsequently
aspirated dry and cells were lysed by the addition of 400 ml
of warm 0.2% SDS. The amount of accumulated radioactivity
was estimated in 50% of the cell lysate via liquid scintillation
counting (Packard TriCarb 4000 scintillation counter). Total
protein content per well was determined using the BCA assay
(Pierce). Readings of c.p.m. are expressed as c.p.m./mg of
protein.
Toxicity bioassay
Astrocytes were washed twice and then incubated for 45–90
min with a medium containing glutamate: the final well
volume equalled 75 or 100 mM. Culture medium from six
wells was removed, pooled and then combined with the
neuronal plating medium and added to the pure neuronal
cultures for the next 16–18 h. Cell viability was assessed using
the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-
tetrazolium bromide] reduction assay (Lobner, 2000), with
minor modifications. MTT (3 mg/ml in PBS) was added to each
well and cultures were placed in a humidified, 6% CO2-
containing incubator at 37 C˚. At least 4 h later, the medium
was aspirated and 400 ml of acidic propan-2-ol was added to
dissolve the formazan salt. A 200 ml portion was transferred
to a 96-well plate and attenuance was measured at 540 nm
using a reference wavelength of 690 nm (Spectramax Plus384;
Molecular Devices). Neuronal cell death was measured in
parallel from the same cells by determination of levels of LDH
(lactate dehydrogenase) released into the cell culture medium
prior to the addition of MTT (Uliasz and Hewett, 2000). Data
are expressed as a percentage of total neuronal LDH activity
(defined as 100%), which was determined in each experiment
by assaying the supernatant of parallel cultures exposed for
16–18 h to 75 or 100 mM glutamate.
Statistical analyses
Data were analysed using one-way ANOVA followed by the
Student–Newman Keul’s test or the Student’s t test to detect
significant differences between two means with P,0.05.
RESULTS
To assess how hypoxic preconditioning might affect the
astrocytes in the immature brain, we first performed
immunofluorescence for GFAP and for S100b. In the
neocortex of control animals, GFAP staining was sparse and
those cells that were GFAP immunoreactive in the gray
matter had long radial processes (Figures 1A and 1C). A
subset of these cells was S100b immunoreactive (Figures 1B
and 1C). In the animals exposed to 3 h of hypoxia 24 h earlier,
the GFAP immunoreactive cells were now more intensely
immunoreactive and they possessed multipolar morphologies
(Figures 1D and 1F). S100b immunoreactivity also was
markedly increased, and in most of S100b-immunoreactive
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cells the S100b was located in the nucleus (Figures 1E and
1F). GFAP and S100b immunoreactivity were also increased in
the CA1-3 layers of the hippocampus and in the dentate
gyrus of the hippocampus (compare Figures 1G and 1I with
Figures 1J and 1L). Again, S100b was nuclear and not
cytoplasmic (Figures 1H–1L). Reflecting the increase in
GFAP immunoreactivity, the expression of GFAP mRNA as
demonstrated by increased hybridization signal was increased
Figure 1 Increase in GFAP and S100B expressions in the preconditioned neonatal rat brain
Vibratome sections from normal (A–C, G–I, M) and preconditioned (D–F, J–L, N) brains at the level of the hippocampus were
processed for GFAP (green) immunofluorescence in combination with S100B (red) from neocortex (A–F) and hippocampal CA2
regions (G–L). Images are Z-stacks from 1 mm confocal Z-sections through 5 mm. Arrows in (E, F, K, L) point to S100B
immunoreactive astroglial nuclei. Other sections were processed for in situ hybridization using a 35S-labelled riboprobe for GFAP, 24
h after exposure to hypoxia. Arrows in (M, N) point to the dentage gyrus and CA2 regions of the hippocampus where the intensity of
GFAP mRNA expression, shown here as white silver grains from the in situ hybridization, was significantly higher in the pre-
conditioned brains. Scale bars: (A–L) 50 mm and (M, N) 1 mm.
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in the hippocampus and the overlying white matter
(Figures 1M and 1N). Sections were also stained for GS, but
it was difficult by immunofluorescence to detect changes in
GS (results not shown).
Western blotting showed that there was a 3-fold increase in
the level of GFAP and an 8-fold increase in the level of GS
compared with controls 24 h after hypoxic preconditioning
(Figures 2A and 2B). Whereas preconditioning in vivo is viewed
as a milder insult that, by definition, does not damage the
brain, prolonged H/I produces cell death and causes significant
astrocyte activation. To evaluate the extent of glial activation,
we exposed a group of preconditioned animals to an additional
episode of 60 min of H/I. Contrary to our expectations, there
was no additional increase in the expression of GFAP and GS in
brains from preconditioned animals that were subsequently
subjected to H/I (Figures 2A and 2B).
As glutamate transporters are essential for buffering
extracellular glutamate, thereby protecting neurons from
excitotoxic stresses under both physiological and pathological
conditions, we next tested whether the preconditioning
paradigm induced the glutamate transporter EAAT-1 (GLAST).
GLAST, like GS, was induced 8-fold in the brains of
Figure 2 Effect of hypoxic preconditioning on GFAP, GS, GLAST,
ceruloplasmin and MCT-1 expression levels in the neonatal rat brain
(A) GFAP, GS and GLAST expression was analysed by Western blotting, with
protein samples extracted from a wedge-shaped section of preconditioned
brains composed of the neocortex, white matter and a portion of the striatum
as described previously (Vannucci et al., 2004). Equivalent regions of the
ipsilateral and contralateral hemispheres of preconditioned animals subjected
to H/I for 60 min and control animals were analysed. Blots were re-probed for
b-tubulin to establish equal protein loading. (B) Densitometric measurements
were carried out on individual immunoblots for each antibody tested and
values represent the means¡S.E.M. for six animals. The solid line represents
the normalized values of the controls. (C) Western-blot analysis of CP and
MCT-1. The fold change in expression levels of CP and MCT-1 in preconditioned
animals over the control is shown. *P,0.05 using the Student’s t test.
Figure 3 Effect of hypoxia in regulating the expression of astrocyte-
specific enzymes and transporters is selective in vitro
Western blot showing the expression of GFAP, GS and GLAST (A) and CP
and MCT-1 (B) in astrocytes exposed to either 21%O2/5% CO2 (atmospheric
condition) or 8% O2 (hypoxic condition) for 3 h in vitro. Results are
representative of results obtained from three independent experiments where
each condition was evaluated in duplicate. Densitometric measurements
were carried out on individual immunoblots for each antibody tested and the
values represent the means¡S.E.M. for three separate experiments. *P,0.05
by the Student’s t test.
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preconditioned animals as compared with naı¨ve controls
(Figures 2A and 2B). As seen with GFAP and GS, the level of
GLAST in the hemispheres of preconditioned animals
subjected to H/I for 60 min was comparable to the induced
level of GLAST in the animals exposed to the preconditioning
stimulus (Figure 2A).
Astrocytes maintain high intracellular concentrations of
certain antioxidants and play an important role in antioxidant
defences in the brain. As oxidative injury is an important
component of H/I cell death, we assessed whether the
antioxidant potential of astrocytes might be altered by a
preconditioning stimulus. Indeed, a 2-fold increase in the ex-
pression of ceruloplasmin was observed in the preconditioned
neonatal rat brain as compared with the normal control
(Figure 2C). As levels of lactate increase during H/I and acidosis
can be neurotoxic, we analysed the expression of MCT-1. MCT-1
levels increased by 2-fold in neonatal rat brains subjected to
hypoxic preconditioning at 24 h of recovery as compared with
naı¨ve control (Figure 2C).
To determine whether these changes are a direct response of
astrocytes to hypoxia, we placed highly enriched cultures of
forebrain type 1 astrocytes (A2B5-negative/GFAP-positive)
produced from the neonatal rat brain into a reduced oxygen
environment (8% O2) for 3 h and analysed protein expression
24 h after returning the cells to an atmospheric environment.
Western-blot analyses revealed a 2-fold increase in the levels
of GS (Figure 3A) as well as MCT-1 in the astrocytes subjected
to hypoxia as compared with the control (Figure 3B).
Interestingly, the expression of GFAP, GLAST and ceruloplasmin
did not change after hypoxia (Figures 3A and 3B), indicating
that some, but not all, of the responses observed in the
preconditioned brain may occur in a cell-autonomous manner.
To determine whether activated astrocytes would protect
neurons from a subsequent glutamate challenge, we assessed
their excitatory amino acid buffering capabilities. For these
studies, astrocytes were treated with dbcAMP, which has been
shown to increase astrocytic morphological complexity, GFAP
and vimentin immunoreactivity as well as other functional
properties of activated astrocytes (Fedoroff et al., 1984;
Eddleston and Mucke, 1993). dbcAMP was chosen since the in
vitro hypoxia was insufficient to induce glutamate transporter
expression, whereas dbcAMP is known to do so (Gegelashvili
Figure 4 dbcAMP increases astrocytic glutamate uptake and metabolism proteins
Rat astrocytes were treated with a medium alone (lanes 1 and 3) or with a medium containing 0.25 mM dbcAMP (lanes 2 and 4) for 7
days. Then, 5 mg (A) or 15 mg (B) of protein was analysed by Western blotting for GS (A) and GLT-1 (B). Densitometric measurements
were carried out on individual immunoblots for each antibody tested. Values represent the means¡S.E.M. for eight individual
experiments. Values below the bars represent the mean fold increase in protein expression that followed dbcAMP treatment. *P,0.05
by the unpaired Student’s t test following Welch’s correction for unequal variances. (C) Astrocyte cultures were treated with dbcAMP
(0.25 mM) for 8 days. The uptake of D-[3H]aspartate (0.1 mCi/ml) was measured at 3 min. Results shown are expressed as c.p.m./mg of
protein per 3 min and are the means¡S.E.M. (n512 culture wells from three separate experiments). The value above the bar
represents the mean fold increase of D-[3H]aspartate uptake after treatment with dbcAMP. *P,0.05 by the unpaired Student’s t test
(P,0.05).
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et al., 1996; Swanson et al., 1997). Astrocytes stimulated with
dbcAMP adopted a stellate morphology that was accompanied
by a 1.7-fold increase in GS and a 2.2-fold increase in GLT-1
expression (Figures 4A and 4B). This increase in glutamate
clearing proteins was accompanied by a 1.9-fold increase in
functional excitatory amino acid uptake as measured using D-
[3H]aspartate (Figure 4C). dbcAMP did not increase levels of CP
in these rat astrocyte cultures (Supplementary Figure S1 avail-
able at http://www.asnneuro.org/an/003/an003e062add.htm).
To determine whether the dbcAMP-stimulated astrocytes
would prevent neuronal cell death on challenge using an
excitotoxic stimulus, HBSS containing glutamate was added to
the astrocytes for 45–90 min, after which the buffer was col-
lected and transferred to pure neuronal cultures. After 16–18 h,
neuronal cell viability was determined using MTT (Figures 5A
and 5B) and LDH (Figures 5C and 5D) assays. Highly enriched
neuron cultures exposed to glutamate-containing medium
transferred from dbcAMP-treated astrocytes were two to four
times less likely to die than cells exposed to glutamate-
containing medium transferred from untreated astrocytes
(Figure 5). Of note, this protective effect was both time and
concentration dependent such that higher concentrations
(Figures 5B and 5D) of glutamate took a longer time to become
detoxified than lower concentrations (Figures 5A and 5C). For
example, only 60% of the neurons were viable as assessed by
the MTT assay after being incubated with a medium that
originally contained 100 mM glutamate and was detoxified
by the dbcAMP-treated astrocytes for 75 min, whereas 90% of
the neurons were viable when 75 mM glutamate was used
(Figures 5B and 5D compared with Figures 5A and 5C).
DISCUSSION
Multiple pathogenetic mechanisms contribute to H/I injury
to the brain, such as inadequate blood flow autoregulation,
elevated extracellular excitatory amino acids, altered cerebral
metabolism, accumulation of toxic metabolites, elevated
intracellular calcium, release of cytokines and prostaglandins,
iron accumulation and overproduction of free radicals.
Hypoxic preconditioning can mitigate the detrimental ef-
fects of H/I on neurons by inducing endogenous adaptive
mechanisms that can protect the perinatal brain from
subsequent injury. Many in vivo and in vitro studies were
designed to determine how preconditioning induces adaptive
responses in neurons. Despite the importance of astrocytes in
maintaining brain homoeostasis, fewer studies have been
conducted to distinguish the direct effects of hypoxic
preconditioning on astrocytes, which might then provide
neuroprotection. Of those studies that have evaluated
astroglial responses to preconditioning stimuli, except for a
few (Brucklacher et al., 2002; Jones and Bergeron, 2004;
Figure 5 dbcAMP-preconditioned astrocytes have an enhanced capacity to protect neurons from glutamate excitotoxicity
Rat astrocytes were treated with a medium alone [(2)dbcAMP] or with a medium containing 0.25 mM dbcAMP [(+) dbcAMP] for 8
days. Glutamate was added to the astrocytes for 45–90 min after which the buffer was collected and transferred to highly enriched
murine neuronal cultures. After 16–18 h, neuronal cell viability was determined using the MTT (A, B) or LDH assay (C, D) (n54–6
from three separate experiments). An asterisk indicates a value significantly different from the control (0 min), which were cultures
exposed to a final concentration of 75 mM (A, C) or 100 mM (B, D) glutamate for 16–18 h. The symbol ‘#’ indicates a significant
between-group difference. Results were analysed using one-way ANOVA followed by the Student–Newman Keul’s test after an
appropriate transformation of percentile data (P,0.05).
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Cimarosti et al., 2005), most have studied astrocytes in the
adult brain (Trendelenburg and Dirnagl, 2005). Therefore the
present study was designed to determine how immature
astrocytes would respond to a preconditioning stimulus and
to test the hypothesis that preconditioning paradigms induce
adaptive responses from astrocytes, enabling them to protect
neurons from the assortment of noxious signals generated
after a more severe hypoxic episode.
Our results on preconditioning-induced tolerance provide
several novel insights: (i) hypoxic preconditioning leads to
the precocious differentiation of neocortical astrocytes; (ii)
preconditioning induces nuclear S100B, which has been
implicated in glial differentiation; (iii) preconditioning
increases the expression of astrocytic GS and GLAST, mediators
crucial for detoxifying extracellular glutamate; (iv) precondi-
tioning induces the expression of ceruloplasmin and MCT-1,
thereby enhancing lactate transport and antioxidant functions
of astrocytes respectively; (v) hypoxic preconditioning strongly
activates astrocytes since no further activation was solicited
after a subsequent exposure to 60 min of H/I; (vi) a subset of
these responses are cell autonomous as they are elicited by
exposing astrocytes in vitro to hypoxia; (vii) changes in
glutamate transporter expression correlate with the buffering
capability of astrocytes for glutamate and protect neurons
from an excitotoxic insult.
Progress has been made in understanding the role of
astrocytes in ischaemic injury (Nedergaard and Dirnagl, 2005).
There is solid evidence that astrocytes can critically influence
neuronal survival during ischaemia and other brain insults.
Astrocytes can protect neurons by providing trophic support,
for example by releasing erythropoietin, which can inhibit
neuronal apoptosis (Ruscher et al., 2002). Oxygen–glucose
deprivation or treating astrocytes with pharmacological
agents that stabilize hypoxia-inducing factors increases the
production and secretion of VEGF (vascular endothelial
growth factor) and erythropoietin (Chavez et al., 2006; Chu
et al., 2010). Astrocytes also scavenge oxygen free radicals via
g lutath ione , meta l loth ioneins or ceru loplasmin
(Trendelenburg et al., 2002). Furthermore, studies have shown
that the glycogen accumulates in the brain after a traumatic
or metabolic insult, which might be protective (Folbergrova
et al., 1996). Astrocytes are the principal repositories of
glycogen in the brain, and experimentally induced increases
in astrocytic glycogen protect neurons in vitro from
ischaemia and glucose deprivation (Swanson and Choi,
1993; Wender et al., 2000). Recent studies in immature brain
have shown that hypoxic preconditioning increases brain
glycogen and this additional pool of metabolic fuel delays
energy depletion during H/I (Brucklacher et al., 2002). These
studies provided the impetus for the present study to test the
involvement of astrocytes in hypoxic preconditioning-
induced neuroprotection.
However, in the neonatal brain, many astrocytes are
immature and thus might be less competent to provide
neuroprotection. Using confocal microscopy for GFAP we were
struck by the finding that there were far fewer GFAP-positive
radial cells in the neocortices of rats exposed to hypoxia 24 h
earlier compared with controls. Moreover, when we stained for
S100B, which is expressed by mature astrocytes, we found
that S100B staining was increased. However, whereas S100B
is expressed in both the nuclei and processes of mature
astrocytes, S100B was solely nuclear. Studies of S100B
function in gliogenesis have shown that S100B is expressed
at high levels in oligodendrocyte progenitors that are
beginning to differentiate and that S100B is lost as they
mature. In S100B-null mice, oligodendrocyte maturation is
delayed, supporting the conclusion that S100B promotes
oligodendrocyte differentiation. In contrast, S100B begins to
be expressed by astrocyte precursors during the first week of
life in rats and mice and is expressed at even higher levels in
mature astrocytes. In neither lineage has it been established
how S100B promotes differentiation; however, S100B has
been shown to increase the activity of the nuclear kinase NDR
(nuclear Dbf2-related) (Deloulme et al., 2004).
Our findings are similar to those of Sizonenko et al. (2007),
who found that H/I brain damage in P3 rat pups disrupted the
normal radial glial architecture, distorted the radial pattern of
Nestin immunostaining, increased GFAP-immunopositive
astrocytes and reduced neocortical fractional anisotropy by
magnetic resonance imaging (Sizonenko et al., 2007). H/I at
P3 produces neuronal cell death, which complicates any
interpretation of the causes of the alterations in the radial
glial cells. With 3 h of hypoxia at P5, there is virtually no
increase in neuronal cell death; therefore, our results suggest
that neonatal hypoxia is sufficient to induce the premature
differentiation of radial glial cells into astrocytes.
Our GFAP in situ hybridization, immunohistochemistry and
Western-blot results revealed that hypoxia alone was sufficient
to elevate GFAP expression in the preconditioned brain
compared with the normal. Whereas the function of GFAP
has long been rather elusive, there are recent studies showing
that GFAP interacts with GLAST through a PDZ domain on
GLAST and that increasing levels of GFAP will increase the
levels of GLAST as well as [3H]aspartate uptake (Sullivan et al.,
2007a). Furthermore, GFAP and GLAST levels both decrease
subsequent to neonatal hypoxic brain injury, and the regions
where these proteins are lost correspond to brain areas that are
most susceptible to injury. Preconditioning, by inducing levels
of GFAP, may thus prevent the loss of GFAP during the H/I
insult, thus preserving levels of GLAST, which in turn would
limit glutamate accumulation and excitotoxicity (Sullivan
et al., 2007b).
Astrocytes have the innate capacity to promote neuronal
survival and have been shown to limit neuronal death from
excitotoxins (Rosenberg and Aizenman, 1989), oxidants
(Wilson, 1997; Dringen et al., 2000) and other stressors.
Glutamate is not only the predominant excitatory neuro-
transmitter in the CNS (Fonnum, 1984; Anderson and
Swanson, 2000; Danbolt, 2001) but it is also a potent
neurotoxin whose excitotoxicity has been implicated in
triggering neuronal death in ischaemia (Takagi et al., 1993;
Vannucci et al., 1999). The rapid removal of glutamate from
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the extracellular space is required for the survival and normal
functioning of neurons, and the energy-dependent glial
glutamate transporter has been shown to be important for
sustaining neuronal functions (Anderson and Swanson, 2000;
Voutsinos-Porche et al., 2003). Moreover, glutamate is
predominantly converted into glutamine in astrocytes by
the enzyme GS and returned to neurons in order to replenish
the presynaptic neurotransmitter pool to maintain synaptic
transmission (Sibson et al., 2001). GS also increases after
ischaemia (Petito et al., 1992). Therefore the capacity of
astrocytes to reduce extracellular levels of glutamate can
dramatically impact the extent of neuronal damage after an
insult. Given the complications associated with administering
NMDA (N-methyl-D-aspartate) receptor antagonists to the
developing brain, enhancing astrocytic glutamate detoxifica-
tion may represent a novel alternative means of providing
neuroprotection after a developmental brain injury
(Ikonomidou et al., 1999).
Glutamate transporters are necessary in order to maintain
resting levels of glutamate, and effective glutamate uptake
by astrocytes prevents glutamate neurotoxicity (Rothstein
et al., 1996; Tanaka et al., 1997). Previous studies have shown
that b-lactam antibiotics, which are potent stimulators of
glutamate transporters, offer neuroprotection by increasing
the transporter expression (Rothstein et al., 2005). More-
over, the expression of the glutamate transporter EAAT-2
increases significantly in the cortex 24 h after hypoxic pre-
conditioning (Cimarosti et al., 2005). We therefore measured
the levels of GS and GLAST to understand whether precon-
ditioning regulates the astrocytic capacity to handle elevated
glutamate that would, in turn, be instrumental in shaping the
kinetics of glutamatergic synaptic activity during subsequent
H/I. Immunoblot analysis revealed an 8-fold increase in
the levels of both GS and GLAST in the forebrain of the
preconditioned animals as compared with the normal. Since
GS and GLAST are almost exclusively produced by astrocytes
(Danbolt, 2001), our results suggest that astrocytes could play
a crucial role in hypoxic preconditioning-mediated neuro-
protection by metabolically reducing excess glutamate in the
preconditioned brain. Furthermore, our results show that
once induced, the levels of GS and GLAST are maintained,
suggesting a long half-life, so that they are readily available
to detoxify the extraordinarily high levels of glutamate that
are released subsequent to an H/I episode.
Increased iron accumulation and overproduction of free
radicals have been associated with neuronal damage caused
by H/I (Palmer et al., 1999; Wallin et al., 2000). Our in vivo
studies revealed a 2-fold increase in the levels of cerulo-
plasmin in the preconditioned brain. As ceruloplasmin is a
multifunctional protein that is expressed by astrocytes and
that can serve as an amine oxidase, an antioxidant or a
ferroxidase, a testable prediction (which future studies could
evaluate) is that higher levels of ceruloplasmin should protect
neural cells from oxidative stress (Patel et al., 2002).
To investigate whether all these changes are a direct
response of astrocytes to hypoxia, we studied the effects of
reduced oxygen on primary astrocyte cultures. Similar to the
results obtained in vivo, exposure to hypoxia in vitro
increased the levels of GS and MCT-1, although to a lesser
extent. However, in contrast with the in vivo condition, there
was no change in the levels of GFAP, GLAST or ceruloplasmin.
Thus hypoxia regulates the expression of a subset of
astrocyte-specific enzymes and transporters. These differ-
ences are likely attributable to the inability of astrocyte
cultures to faithfully mimic the in vivo environment. In
support of this hypothesis, we have observed that reducing
the volume of medium overlying cultured astrocytes reduces
MCT-1 expression as well as glucose utilization, consistent
with the interpretation that under standard in vitro culture
conditions the astrocytes are hypoxic due to poor solubility of
O2 in the culture medium (S.W. Levison and I. Simpson,
unpublished data). Moreover, it has been well established that
there are multiple astrocyte populations in vivo. Hence, these
cells may not adequately model the responses of every type
of astrocyte in vivo.
That GLAST and ceruloplasmin were not induced in the
astrocytes in vitro in direct response to hypoxia suggests that
additional signals are necessary for their induction. One likely
possibility is that signals from activated microglia are
necessary. Indeed in earlier studies we showed that IL-1
(interleukin-1) induced ceruloplasmin and that ceruloplasmin
was not induced in mice lacking the IL-1 type 1 receptor.
However, the observation that neither ceruloplasmin nor
GLAST was induced in the mixed brain cultures where microglia
were certainly present would argue against this hypothesis.
At a critical threshold, H/I will overwhelm the normal
capacity of astrocytes to maintain metabolic homoeostasis,
resulting in the depletion of energy substrates, neuronal
overexcitation and accumulation of toxic by-products of
metabolism that are detrimental to neuronal viability. Our
studies add to the emerging body of literature that supports
the view that preconditioning triggers metabolic reprogram-
ming by inducing the expression of proteins involved in the
supply and demand pathways of metabolism, thus shifting
the threshold where damage will occur. Investigating the
mechanisms by which astrocytes respond to hypoxic pre-
conditioning could be a productive focus for future research
on the mechanisms of neuroprotection, which could lead to
the identification of new small molecules that could activate
astrocytes, mimicking the preconditioning stimulus with
therapeutic benefits. However, caution is needed when
applying these findings to newborns as it is conceivable that
the precocious transformation of radial glial cells into mature
astrocytes could have a deleterious rather than a beneficial
outcome.
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